A U.S. House Select Committee investigation expanded focus on clinical trials conducted by U.S. companies at Chinese military hospitals and in Xinjiang, raising questions about patient safety oversight and research ethics. Separately, data transparency issues remained in the spotlight as China-linked clinical evidence faced ongoing journal- and regulator-driven challenges. The combined scrutiny is likely to increase compliance costs and alter trial sourcing decisions for global developers evaluating faster enrollment and diverse patient cohorts.